I am going to talk about the pathophysiology of type 2 diabetes, because most new treatments are now being designed based on our understanding of the pathophysiology. I will discuss some epidemiology, but will spend most of my time on pathophysiology, and conclude with the diagnosis of diabetes and goals of treatment.
In an observational study, concurrent proton-pump inhibitor use was associated with a dose-dependent loss of protection against hip fracture treatment in elderly patients. Medscape Medical News
In a randomized controlled trial, metformin extended release caused a small but statistically significant decrease in body mass index when added to a lifestyle intervention program. Medscape Medical News
